Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NP97
UPID:
DLRB1_HUMAN
Alternative names:
Bithoraxoid-like protein; Dynein light chain 2A, cytoplasmic; Dynein-associated protein Km23; Roadblock domain-containing protein 1
Alternative UPACC:
Q9NP97; B1AKR5; Q5TC72; Q96IV3; Q9NQM2
Background:
Dynein light chain roadblock-type 1, also known as Dynein light chain 2A, cytoplasmic, plays a crucial role in the cytoplasmic dynein 1 complex. This protein is essential for the retrograde motility of vesicles and organelles along microtubules, facilitating intracellular transport.
Therapeutic significance:
Understanding the role of Dynein light chain roadblock-type 1 could open doors to potential therapeutic strategies.